183 related articles for article (PubMed ID: 33460496)
1. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
Bartels S; Vogtmann J; Schipper E; Büsche G; Schlue J; Lehmann U; Kreipe H
Eur J Haematol; 2021 Apr; 106(4):520-528. PubMed ID: 33460496
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
3. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
5. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
6. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
9. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.
Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
Leukemia; 2020 May; 34(5):1364-1372. PubMed ID: 31776465
[TBL] [Abstract][Full Text] [Related]
10. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Pardanani A; Lasho TL; Finke CM; Mai M; McClure RF; Tefferi A
Leukemia; 2010 Jun; 24(6):1146-51. PubMed ID: 20410924
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms].
Han X; Bai BB; Feng CC; Zhao S; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):190-196. PubMed ID: 38387920
[TBL] [Abstract][Full Text] [Related]
13. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
14. [Bone marrow fibrosis in primary myelofibrosis in relation to myelodysplasia- and age-related mutations of hematopoietic cells].
Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
Pathologe; 2020 Dec; 41(Suppl 2):124-128. PubMed ID: 33113046
[TBL] [Abstract][Full Text] [Related]
15. Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
Loscocco GG; Guglielmelli P; Vannucchi AM
Onco Targets Ther; 2020; 13():12367-12382. PubMed ID: 33293830
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].
Tan YX; Xu N; Huang JX; Wu WE; Liu L; Zhou LL; Liu XL; Yin CX; Xu D; Zhou X
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):576-582. PubMed ID: 32810965
[No Abstract] [Full Text] [Related]
17. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
18. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.
Gaidano G; Pastore C; Santini V; Nomdedeu J; Gamberi B; Capello D; Vischia F; Resegotti L; Mazza U; Ferrini PR; Lo Coco F; Saglio G
Genes Chromosomes Cancer; 1997 Aug; 19(4):250-5. PubMed ID: 9258660
[TBL] [Abstract][Full Text] [Related]
19. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
Chen D; Fuda F; Weinberg O
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
[TBL] [Abstract][Full Text] [Related]
20. Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis.
Li B; Gale RP; Xu Z; Qin T; Song Z; Zhang P; Bai J; Zhang L; Zhang Y; Liu J; Huang G; Xiao Z
J Hematol Oncol; 2017 May; 10(1):99. PubMed ID: 28464892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
